Helping Alzheimer’s patient’s brain “shine” again
Decreased insulin sensitivity of brain cells represents an important step in the pathogenesis of Alzheimer’s disease. Insulin resistance is present in all patients with type 2 diabetes mellitus, but also in one-third of “healthy” adult individuals.
Previous research has shown that improvement in insulin sensitivity may decrease the intensity of symptoms in patients with Alzheimer’s disease with a consequently increased glucose uptake on FDG-PET scans. GLP-1 agonists are currently the most powerful weapon in the battle against insulin resistance. The role of GLP-1 agonists in the treatment of early Alzheimer’s disease has entered phase 3 clinical trial for the first time in history.
Give your patients with Alzheimer’s disease an opportunity to regain some of their sharpness by contacting us to enroll in the trial.